Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Allogene Therapeutics Inc (ALLO)

Allogene Therapeutics Inc (ALLO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 429,828
  • Shares Outstanding, K 209,672
  • Annual Sales, $ 100 K
  • Annual Income, $ -327,270 K
  • EBIT $ -276 M
  • EBITDA $ -268 M
  • 60-Month Beta 0.84
  • Price/Sales 4,679.00
  • Price/Cash Flow N/A
  • Price/Book 0.96

Options Overview Details

View History
  • Implied Volatility 149.84% ( +22.93%)
  • Historical Volatility 83.96%
  • IV Percentile 87%
  • IV Rank 21.02%
  • IV High 678.39% on 05/17/24
  • IV Low 9.15% on 08/15/24
  • Put/Call Vol Ratio 2.50
  • Today's Volume 14
  • Volume Avg (30-Day) 86
  • Put/Call OI Ratio 0.14
  • Today's Open Interest 3,642
  • Open Int (30-Day) 5,722

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.34
  • Number of Estimates 12
  • High Estimate -0.25
  • Low Estimate -0.51
  • Prior Year -0.43
  • Growth Rate Est. (year over year) +20.93%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.99 +6.03%
on 11/20/24
3.36 -37.20%
on 11/07/24
-0.69 (-24.64%)
since 10/21/24
3-Month
1.99 +6.03%
on 11/20/24
3.36 -37.20%
on 11/07/24
-0.63 (-22.99%)
since 08/21/24
52-Week
1.99 +6.03%
on 11/20/24
5.78 -63.46%
on 03/08/24
-0.71 (-25.18%)
since 11/21/23

Most Recent Stories

More News
Allogene Therapeutics Announces Participation in December Investor Conferences

ALLO : 2.11 (+2.93%)
Allogene Therapeutics Announces Promising Preclinical Data for ALLO-329, an AlloCAR Tâ„¢ Therapy Targeting Autoimmune Diseases

ALLO-329 shows promise in treating autoimmune diseases by targeting CD19+ B cells and CD70+ T cells without lymphodepletion.Quiver AI SummaryAllogene Therapeutics has announced promising preclinical data...

ALLO : 2.11 (+2.93%)
Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence

ALLO : 2.11 (+2.93%)
Allogene Therapeutics: Q3 Earnings Snapshot

Allogene Therapeutics: Q3 Earnings Snapshot

ALLO : 2.11 (+2.93%)
Allogene Therapeutics Reports Third Quarter 2024 Financial Results and Business Update

ALLO : 2.11 (+2.93%)
Allogene Therapeutics Announces Positive Phase 1 Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Patients with Advanced Renal Cell Carcinoma at SITC and IKCS

ALLO : 2.11 (+2.93%)
Allogene Therapeutics to Present New Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Adult Patients with CD70 Positive Advanced Renal Cell Carcinoma (RCC) at the International Kidney Cancer Symposium (IKCS) and Society for...

ALLO : 2.11 (+2.93%)
Allogene Therapeutics Announces Participation in November Investor Conferences

ALLO : 2.11 (+2.93%)
Allogene Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update

ALLO : 2.11 (+2.93%)
Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ALLO-316, an AlloCAR Tâ„¢ Investigational Product for Adult Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)

ALLO : 2.11 (+2.93%)

Business Summary

Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company, primarily focused on the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer.'

See More

Key Turning Points

3rd Resistance Point 2.30
2nd Resistance Point 2.22
1st Resistance Point 2.16
Last Price 2.11
1st Support Level 2.03
2nd Support Level 1.95
3rd Support Level 1.89

See More

52-Week High 5.78
Fibonacci 61.8% 4.33
Fibonacci 50% 3.88
Fibonacci 38.2% 3.44
Last Price 2.11
52-Week Low 1.99

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar